News Hub | News Direct
Back

peran+perawat+dalam+pencegahan+gagal+ventilasi+pada+pasien+covid+19


Article thumbnail News Release

I-ON Digital Corp. Announces Shareholder Update and Management Discussion

I-ON Digital Corp.

I-ON Digital Corp. (the “Company”) (OTC: IONI), a leading innovator in gold, precious metals, and RWA (real-world asset) digitization, tokenization and digital banking solutions, is pleased to announce the scheduling of a Shareholder Update and Management Discussion on Friday, September 20, 2024, at 5:00PM EDT (2:00PM PDT). The discussion will provide shareholders with an opportunity to hear directly from the Company's executive team about the 2023 and 2024 year-to-date financial results and as reported in the Company's recent filings with the U.S. Securities and Exchange Commission (“SEC”) and further updates on the Company's strategic direction for the balance of 2024 and 2025. "We are looking forward to discussing the Company ’ s financial results and sharing our strategic vision with our shareholders," said Carlos X. Montoya, CEO of I-ON Digital Corp. "Our company has made significant progress in advancing our asset digitization and tokenization solutions, and we look forward to discussing our achievements and future plans with our valued shareholders." Shareholders are encouraged to review the Company ’ s Annual Report on Form 10-K for the year ended December 31, 2023, along with 2024 quarterly reports for the first and second quarters which are available on the SEC's website and on the company's investor relations page at https://iondigitalcorp.com/. To participate in the shareholder discussion, please follow this link https://iondigitalcorp.com/ion-digital-corp-investor-relations/. About I-ON Digital Corp. I-ON Digital Corp. (OTC: IONI) is a leading innovator in gold, precious metals, and RWA (real-world asset) digitization, tokenization and digital banking solutions. Our services are engineered to provide a secure, fast, transparent, and institutional-grade ecosystem that digitizes documentary evidence of gold reserve ownership into secure, asset-backed digital securities. This process brings liquidity and accepted value to a wide array of asset classes. Additional information is available at https://iondigitalcorp.com/. Forward-Looking Statements This news release contains forward-looking statements involving risks and uncertainties, which may cause results to differ materially from the statements made. When used in this document, the words "may," "would," "could," "will," "intend," "look to," plan," "anticipate," "believe," "estimate," "expect," "seek," "potential," "outlook," and similar expressions are intended to identify forward-looking statements. Such statements, including, but not limited to, I-ON's current views with respect to future events and its financial forecasts, are subject to such risks and uncertainties. Many factors could cause actual results to differ materially from the statements made, including those risks described from time to time in filings made by I-ON with the Securities and Exchange Commission. In addition, there is uncertainty about the further spread of the COVID-19 virus or new variants thereof or the occurrence of another wave of cases and the impact it may have on the Company's operations, the demand for the Company's products, global supply chains, and economic activity in general. These and other risks and uncertainties are detailed in the Company's filings with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, or expected. Statements in this news release regarding past trends or activities should not be taken as a representation that such trends or activities will continue. I-ON does not intend or assume any obligation to update these forward-looking statements other than as required by law. Contact Details I-ON Digital Corp. Investor Relations +1 866-440-2278 IR@iondigitalcorp.com Company Website https://iondigitalcorp.com

September 18, 2024 08:00 AM Eastern Daylight Time

Article thumbnail News Release

With The Effective End Of The 6% Real Estate Commission Standard, reAlpha’s AI-Powered Homebuying Platform Hopes To Shake Up The Industry

Benzinga

By Meg Flippin, Benzinga The 6% commission standard on real estate deals is expected to be no more, potentially lowering the cost of owning a home. The change is part of a $418 million class-action lawsuit settlement against the National Association of Realtors (NAR), which was accused of inflating the fees paid to real estate agents. Thanks to the settlement, the commission is up for negotiation, which some estimate could result in a 25% to 50% decrease in commission fees that just last year cost Americans $100 billion. This change to the real estate market could also help pave the way for companies providing buyers with tools to streamline the homebuying process, such as reAlpha Tech Corp. (NASDAQ: AIRE). The Dublin, Ohio real estate technology company says it is experiencing strong growth thanks to the launch of its artificial intelligence (AI)-powered, commission-free home buying platform. Buying A Home Can Be Much Easier reAlpha’s AI platform guides users through every stage of the homebuying process and is currently available in 20 Florida counties, with plans for expansion. The platform leverages AI to help customers find homes, make an offer, get a mortgage and close the deal. With reAlpha, users pay zero buy-side commissions, and the company plans to make money by collecting closing costs of 1.2% to 2.47% via mortgage brokering, title and search and home insurance services. reAlpha’s launch comes as the AI market is taking off, forecast to grow to $1.8 trillion by 2030. Advances in machine learning and automation are enabling tech-focused companies to develop AI models that are disrupting many industries. Real estate could also use some innovation, and reAlpha is attempting to capitalize on that, hoping to disrupt the way Robinhood Markets Inc. (NASDAQ: HOOD) did with online investing or Expedia Group Inc. (NASDAQ: EXPE) did for travel. Growing Revenue For Q2 this year, reAlpha reported quarter-over-quarter revenue that rose 205%. The company also closed its buy of Naamche, Inc., a Nepal-based AI technology firm. This acquisition bolstered reAlpha's AI capabilities by adding 42 engineers, developers, analysts and UI/UX designers to its team, increasing the company’s full-time employee count from 15 to 57. reAlpha said the acquisition marks the beginning of the company’s acquisition-led growth strategy, which it said aims to revolutionize the real estate industry through cutting-edge technology. More To Come "We believe that the completion of the Naamche acquisition marked the second quarter of 2024 as the beginning of the ramp-up of our acquisition-led growth strategy," said Giri Devanur, CEO of reAlpha. "We are continuously looking for strategic acquisition opportunities that will advance our mission of bringing innovative technologies to the real estate industry. Naamche's acquisition is one of the early steps in this process." Other acquisitions include AiChat, a Singapore-based company that develops AI-powered conversational customer experience solutions and Hyperfast Title LLC., a title company that’s licensed to operate in Florida, Virginia and Tennessee. With it, reAlpha can offer title services through its platform. Now, reAlpha has added another key piece to its portfolio with the acquisition of Be My Neighbor, a mortgage broker licensed in 26 U.S. states. The company says this acquisition strengthens reAlpha’s AI-powered homebuying platform by incorporating mortgage lending and refinancing services, allowing for a more integrated and seamless customer experience. Be My Neighbor, founded by veterans, will continue to operate under its own brand while leveraging reAlpha's generative AI capabilities. This move is part of reAlpha's broader strategy to vertically integrate the homebuying process, which it says should enhance its commission-free platform and unlock new revenue streams. Looking toward the third quarter, reAlpha is forecasting quarter-over-quarter revenue growth of 140% to 170% in Q3, driven by the integration of its newly acquired companies, AiChat and Hyperfast Title. reAlpha said these acquisitions are expected to enhance its service offerings and contribute significantly to its overall revenue. Taking A Page From Constellation Software reAlpha is only just getting started. The company says it is on the hunt for even more acquisitions as it grows, taking a page from Constellation Software (TSX: CSU ), a Canadian software and services company that has a reputation for acquiring hundreds of software businesses. reAlpha says it hopes to position itself as a trailblazer in the real estate technology sector by strategically acquiring accretive real estate service and technology companies centered around its core platform. “We intend to capitalize on a significant industry shakeup created by the NAR lawsuit. We developed and launched the reAlpha platform after the settlement was announced on March 15, 2024. We are focused on continually improving the product and acquiring additional real estate service companies to unlock more potential sources of revenue,” said Devanur. “We look forward to sharing our growth and developments in the coming quarters, especially after the effects of the NAR settlement take effect on August 17, 2024,” he said. New CFO reAlpha recently announced the appointment of Brent Miller as their new Chief Financial Officer (CFO). Miller, who officially took on the role on Aug. 19, 2024, will be responsible for all financial and accounting operations at reAlpha, reporting directly to the company's president and Chief Operating Officer, Mike Logozzo. Notably, Miller brings valuable experience from his previous role as CFO and treasurer at KKR Real Estate Finance Trust Inc., a commercial mortgage real estate investment trust. During his time there, Miller played a key role in shaping the REIT’s financial strategy, including capital raising and financial reporting. His background with KKR underscores his expertise and makes his appointment at reAlpha a significant development for the company. Featured photo courtesy of reAlpha Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 12, 2024 08:25 AM Eastern Daylight Time

Image
Article thumbnail News Release

Armed With Its Patent Portfolio, BioRestorative Therapies Has Success In The Laboratory And At The Negotiating Table: Is Profitability Close Behind?

Benzinga

By Anthony Termini BioRestorative Therapies (NASDAQ: BRTX) is a clinical-stage biotechnology company involved in various clinical trials involving its patented approach for using stem cell therapy to treat a number of disorders. The company has, in recent months, issued updates on its earnings and operations, and it is developing a promising treatment program to treat diabetes and obesity. Quarterly Report Highlights The company issued its second quarter 2024 business update in August, and a number of announcements accompanied their reported financials. BioRestorative announced that preliminary clinical data related to its “Disc/Spine Program” showed meaningful signals and no notable safety markers in patients enrolled in a clinical study of BRTX-100 as a treatment for chronic lumbar disc disease. Also, following manufacturing/clinical process enhancements made by BioRestorative that tripled its monthly trial capacity, it guided that it was targeting completion of patient enrollment in the phase 2 BRTX-100 study in chronic lumbar disc disease (cLDD) by the end of 2024. The company also plans to provide additional preliminary data updates by then. Furthermore, BioRestorative said that it has also laid the foundation for the commercialization of its BioCosmeceuticals business, which could begin generating significant revenues this year. The company noted that it inked an agreement to supply its proprietary cell-based biologic serum to Cartessa Aesthetics, LLC. An analysis of the company’s June 30, 2024 Form 10-Q revealed a 19% improvement in year-over-year operations, with net loss narrowed to $2.5 million compared to a $3.1 million loss in the prior period. BioRestorative’s balance sheet showed some $14.7 million on hand at the end of June. Lance Alstodt, BioRestorative’s Chief Executive Officer, noted that these accomplishments “will provide additional financial flexibility” and bolster the company’s strategy to execute and accomplish important long-term goals. The quarterly report also discussed BioRestorative’s expansion of its core preclinical program for ThermoStem®. “Metabolic Program” Addresses Important And Lucrative Markets One of the more significant opportunities that BioRestorative is pursuing is related to its ThermoStem platform. Currently in preclinical testing, the intended therapy is to target obesity and metabolic disorders (like diabetes) using stem cells to generate a type of body fat that regulates metabolic homeostasis. A recent report from the Centers for Disease Control and Prevention demonstrates that nearly 42% of adults in the United States suffer from obesity. Those diagnosed with severe obesity were just over 9%. Furthermore, research conducted at Harvard University and George Washington University concluded that “adults with obesity spend an average of $1,861 more a year on medical costs than someone who doesn’t have obesity. People with severe obesity spend an average of $3,097 more.” According to investment firm Goldman Sachs, the worldwide market for obesity drugs could be $100 billion by 2030. And there is a link between obesity and diabetes. The American Heart Association says that obesity contributes to up to half of new diabetes cases annually in the United States. Treating this disease also represents a significant market opportunity for BioRestorative. Precedence Research expects the global diabetes drug market to reach about $132 billion by 2034. The combined market for obesity and diabetes drugs creates a significant opportunity for BioRestorative’s ThermoStem over the next decade. It is important to note that ThermoStem is not restricted to being only a standalone treatment. It may be used with drugs like Novo Nordisk’s (NYSE: NVO) Ozempic or Wegovy, or Eli Lilly’s (NYSE: LLY) Mounjaro, which are already approved for use to treat both obesity and diabetes. “We believe that ThermoStem has immense potential to develop both best-in-class and first-in-class therapies,” said Alstodt. Other Developments Related To BioRestorative’s Intellectual Property Portfolio Also accompanying BioRestorative’s business update announcement were comments related to its broad intellectual property portfolio. Previously published data from a study conducted at the University of Utah School of Medicine showed significant reductions in weight, triglyceride, and blood glucose levels compared to controls. The study also demonstrated that BioRestorative’s 3D scaffold was capable of retaining viable transplanted cells for at least five weeks post-implantation. In June, BioRestorative published a press release announcing that it had received notice of allowance from the Japanese Patent Office for a patent application related to ThermoStem. This is the fifth Japanese patent issued for the ThermoStem technology platform. “We are proactively expanding the already formidable ThermoStem intellectual property estate to help ensure long-term market exclusivity…” and “…this is demonstrated by this new patent allowance,” Alstodt remarked. The company also announced that it is currently involved in substantive discussions with at least one (undisclosed) regenerative medicine company regarding ThermoStem licensing. This, along with the Cartessa agreement, is why the company said that it “is poised to potentially enter into a stage of anticipated rapid growth.” Featured photo by qimono on Pixabay. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 11, 2024 08:35 AM Eastern Daylight Time

Image
Article thumbnail News Release

Aclarion, Inc.’s (NASDAQ: ACON) Emerging Role in the Back Pain Management Sector

ACON

As the healthcare technology sector advances, companies are making significant strides in addressing widespread health challenges. One area experiencing notable innovation is the diagnosis and management of chronic low back pain (cLBP), a condition that affects millions globally and incurs substantial healthcare costs. Aclarion, Inc. (NASDAQ: ACON) is emerging as a key player in this field with its groundbreaking Nociscan platform. Nociscan is an advanced diagnostic tool designed to address the global challenge of chronic low back pain, which impacts approximately 266 million people worldwide. This condition is a major driver of healthcare expenditures, with U.S. costs alone reaching up to $134.5 billion annually. Aclarion’s Nociscan platform stands out as the first evidence-supported software-as-a-service (SaaS) solution that uses Magnetic Resonance spectroscopy (MRS), proprietary signal processing techniques, and augmented intelligence algorithms to noninvasively differentiate between painful and nonpainful discs in the lumbar spine. The Nociscan system operates through a cloud-based platform that processes MRI data to quantify chemical biomarkers associated with disc pain. This data is then analyzed using proprietary algorithms to provide physicians with crucial insights into the potential sources of pain. By integrating Nociscan with traditional diagnostic methods, healthcare providers can achieve greater diagnostic precision and enhance treatment planning, leading to improved patient care. Aclarion, Inc. (NASDAQ: ACON) has recently achieved a significant milestone with its Nociscan platform, announcing the completion of the first Nociscan exams in the LIFEHAB trial. This randomized control trial, conducted in Norway, is pivotal in comparing lumbar interbody fusion surgery with multidisciplinary rehabilitation for chronic low back pain. The trial involves 202 patients and utilized Nociscan’s advanced diagnostic technology to assess how MRS biomarkers can correlate with treatment responses. The LIFEHAB trial began enrollment in Q2 of 2024, and as of late August, six patients have completed their Nociscan exams. Brett Ness, Aclarion’s CEO, highlighted the significance of this development: ““We are excited to see the LIFEHAB Trial progressing on schedule and look forward to the results of the study and to the role we expect Nociscan data to play in not only helping physicians determine which discs to treat but in potentially helping to predict which treatment option is optimal for a particular patient.” This latest achievement showcases ACON’s commitment to advancing chronic low back pain management and demonstrates the growing adoption of Nociscan in research settings. The LIFEHAB trial’s integrations of Nociscan tech represent a crucial step in validating its effectiveness and aligning with Aclarions broader goals of enhaving treatment and outcomes. As ACON continues to make strides, the company has also expended presence in the US market. On August 14, 2024, the company announced a key commercial agreement with Sheridan Community Hospital in Michigan. This partnership marks Aclarion’s entry into central Michigan and involves collaboration with Dr. John Keller, a leading neurosurgeon. This agreement aims to further validate Nociscan’s clinical effectiveness and demonstrates the platform's potential to advance noninvasive, cost-effective diagnostics for disc pain. Building on its success in the UK, where ACON has secured insurance coverage, the company is now focused on achieving similar coverage in the U.S. This is a critical step towards increasing Nociscan’s accessibility and adoption within the American healthcare system. Further expanding its reach, ACON has introduced Nociscan to the personal injury and workers’ compensation markets in New Jersey. Announced on August 29, 2024, this initiative involves Dr. Justin Kubeck, an orthopedic spine surgeon, working to enhance the evaluation of chronic low back pain in these complex legal and insurance settings. This effort aims to provide objective data to support treatment decisions and compensation claims, leveraging Nociscan’s ability to measure biomarkers correlated with pain and structural integrity. In addition to its commercial agreements, Aclarion has launched two major clinical trials to substantiate Nociscan’s benefits. The Clinical Utility and Economic (CLUE) Trial, announced on August 21, 2024, aims to assess how Nociscan’s AI-generated biomarker data impacts surgical treatment decisions. By comparing surgeons’ initial treatment plans with those adjusted after reviewing Nociscan data, the trial seeks to provide valuable real-world evidence of the platform’s effectiveness in improving surgical outcomes. Complementing this, the CLARITY trial—a gold-standard, multicenter, prospective randomized study—will provide definitive evidence on the advantages of incorporating Nociscan data into surgical decision-making processes. Aclarion’s innovative approach has recently garnered industry recognition. On September 5, 2024, ACON was added to the PRISM Emerging Medical Devices Index. This inclusion highlights Aclarion’s position as a leading innovator in the medtech sector. Being part of the PRISM Index validates Aclarion’s technological advancements and can increase its market visibility, credibility, and attractiveness to investors. As the U.S. medical devices market is projected to grow to nearly $315 billion by 2032, Aclarion’s Nociscan is well-positioned to capture a portion of the $40 billion lumbar spine diagnostics and treatment market. ACON’s efforts to address chronic low back pain through innovative, noninvasive technology underscore its potential to make a significant impact in the healthcare sector. With its expanding clinical partnerships, ongoing trials, and recent industry recognition, ACON is positioning itself strongly within the healthcare technology market. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated to assist in the production and distribution of this content. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 Mark@razorpitch.com Company Website http://razorpitch.com

September 11, 2024 06:00 AM Eastern Daylight Time

Article thumbnail News Release

National Land Realty Finds Acreage Prices Remain Stable Through First Semester

National Land Realty

National Land Realty (NLR), the nation's fastest-growing land brokerage firm specializing in farm, ranch, country estates, timber, recreational, and commercial development properties, has released its latest data on land sales across the United States. The report draws from NLR’s network of over 400 agents and brokers in 48 states to provide a year-to-date analysis of Q1 and Q2 agricultural land sales for 2024. It demonstrates stability in the national aggregate for average price per acre (PPA), while highlighting notable trends within outliers like Louisiana, Florida, and California. National Aggregate The data from NLR’s latest report showed that the average price per acre across the country remained relatively stable, having increased by only about 5% nationally. This comes in the wake of significant farmland appreciation over the past few years, with many parts of the country seeing record prices for farmland in 2023. “Land prices have remained high in spite of increased input costs and interest rates, indicating significant demand across the country for irrigated and available farmland. This is largely due to massive consumer demand for produce, meat, dairy, and feed,” said Ronnie Richardson, CEO at NLR. “While further increases are unlikely for the moment, I believe these values will remain strong for the foreseeable future—barring extensive drought, natural disasters, or an industry-shaking event akin to the COVID-19 pandemic.” Louisiana According to NLR, the data found that the average price per acre in Louisiana decreased by $10,866, primarily due to some of the larger landowners beginning to divest themselves of some farmland holdings. “Louisiana is largely farmland, where land values are influenced by the same forces as elsewhere: supply and demand. Price adjustments occur when production costs rise and commodity prices fall,” said Richardson. “Even with a slight decrease in price per acre, purchasing land remains attractive as divestments create opportunities for buyers to capitalize on economies of scale.” California Data revealed that California's average price per acre dropped by $12,226 over the past year—a significant 27% decline. This decrease is likely driven by a combination of high interest rates and low commodity prices for popular crops like almonds and walnuts. Since prices are relatively high in California overall, percentage-based factors like tax or interest-rate hikes hit the California market harder than they do other states. “Reports of an exodus from California real estate have little implications for the agricultural market, which remains generally unaffected by geopolitics. Taxes and interest rates are far more likely to influence the market,” said Richardson. “We do have a couple of large institutional investors looking to exit the California farmland market, but there are no buyers thus far. They may need to adjust their prices to match demand if they are serious about liquidating. With the average price per acre already down, I'd recommend watching the market closely and holding off on purchases for now." Florida In Florida, the average price per acre surged by $24,000 from 2023 to 2024, reflecting a remarkable 118% increase. This significant rise is driven primarily by the soaring demand for land in the state over the past year. Florida remains one of the top destinations for people moving to different states in the US, meaning this demand for available land in Florida isn’t likely to change anytime soon. “It's the same issue here: supply and demand,” said Richardson. “Even though the price per acre is up, I would still recommend buying land in Florida as demand continues to rise. I would focus on transitional properties in particular as more people continue to move into the state. The key to Florida is simple: demand is driving everything." Annex About National Land Realty National Land Realty (NLR) is the nation’s fastest growing real estate land brokerage company specializing in farm, ranch, country estates, timber, recreational, and commercial development properties. Highly regarded for its proprietary land touring technology, Land Tour 360 ®, as well as its GIS land mapping system, LandBase™, which catalogs land data in extremely detailed ways, the company makes it easy to view and zero in on the right property in the right place. Founded in Greenville, S.C. in 2007, NLR has more than 80 offices in 40 states. To learn more visit www.nationalland.com or call (855) 384-5263. Methodological Note The data in the report was derived from a compilation of land sales data provided by National Land Realty’s network of agents across the United States. The report compares 2023 sales data to sales data from the first half of 2024. For the first half of 2024, the data is based on 6,963 land transactions. Note to the editors A table with data for all states where National Land operates is available in the annex. A headshot of Ronnie Richardson, the company logo, and a map illustrating the states where land values are appreciating or depreciating the most can be accessed via this link. Contact Details Razor Sharp PR Jo Detavernier +1 210-803-2097 jo@razorsharppr.com Company Website https://nationalland.com/

September 10, 2024 09:30 AM Central Daylight Time

Article thumbnail News Release

Anthony Milewski Shares His Insights on Junior Mining Stocks

MarketJar

The Oregon Group continues to lead the conversation in market speculation with its latest insights into the junior mining sector. In the latest "Greed, Guts and Glory" newsletter, founder Anthony Milewski delves into the unique challenges and opportunities within this high-stakes arena, framing junior miners as a bold and strategic choice in a high-stakes environment, comparable to the complexities of trading options. Available on The Oregon Group platform, this newsletter is more than just a publication—it's a community. "Greed, Guts and Glory" is designed to build a network of like-minded speculators, offering a space for exchanging ideas, refining strategies, and celebrating market successes. The Strategic Insight: Junior Miners as Options Trades In the volatile world of commodities, success often depends on timing and strategy. Anthony Milewski, with his decades of experience in the sector, offers a fresh perspective on investing in junior mining companies. Instead of viewing these stocks as traditional equity investments, Milewski suggests that they should be approached as "call options" on large, out-of-the-money deposits. Much like options, junior mining stocks come with a significant amount of risk, primarily due to their reliance on commodity price movements and the inevitable need for capital raises. However, this risk also brings the potential for outsized rewards when the timing is right. The key, as Milewski emphasizes, is understanding the underlying commodity and recognizing the signs of an impending market shift. Understanding the Risks and Rewards The junior mining space is notoriously speculative. With only one in three thousand exploration projects ever evolving into a viable mine, the odds are clearly stacked against investors. However, as Milewski points out, it’s this very risk that creates the possibility for exponential returns. For those willing to embrace this high-risk, high-reward dynamic, the approach is clear: buy the dream, capitalize on a favorable commodity move, and sell at the peak of market enthusiasm. This strategy mirrors the approach taken by options traders, where timing is everything, and the ability to exit before the value erodes is crucial. The Importance of Commodity Cycles Central to this strategy is the understanding of commodity cycles. As Milewski notes, the value of a junior mining stock is heavily influenced by the price of the underlying commodity. At a certain price point, any project can become viable, but below that threshold, even the most promising projects may falter. By recognizing where a specific commodity is in its cycle, investors can better gauge when to enter and exit positions in junior mining stocks. This timing, combined with a deep understanding of the project’s potential and its leverage to the commodity, forms the crux of successful speculation in this space. Leveraging Low-Grade Deposits for High Returns Milewski also highlights the potential hidden in large, low-grade deposits that are often overlooked by the market. These projects, while not immediately attractive due to their lower grades, can become highly valuable as commodity prices rise. This leverage to commodity price movements is where significant wealth can be generated. Robert Friedland, a prominent figure in mining, famously stated that “grade doesn’t matter,” a sentiment echoed by Milewski. He argues that it’s just as challenging to permit and develop a small project as it is a large one, so if you’re going to invest, it’s wise to focus on the bigger opportunities with the potential for substantial returns. Timing the Market: A Fine Art Ultimately, the success of this strategy hinges on timing the market correctly. Entering too early can lead to erosion of value due to ongoing capital raises, while waiting too long may mean missing out on the rapid appreciation that can occur as commodity prices shift. The Oregon Group ’s approach is to constantly evaluate these opportunities, focusing first on the commodity and then on the companies with the best leverage to that commodity. While the path to success in junior mining stocks is fraught with risk, the potential rewards make it a compelling consideration for those with the experience and insight to navigate it. A New Perspective on Junior Mining Investments The Oregon Group ’s latest insights offer a compelling framework for understanding and investing in the junior mining sector. By approaching these stocks as options trades, with a clear focus on timing and commodity leverage, investors can position themselves to potentially reap significant rewards. However, as with all speculative investments, the importance of discipline, timing, and a thorough understanding of the market cannot be overstated. For those ready to explore this high-risk, high-reward strategy, staying informed and connected with experts like Anthony Milewski and The Oregon Group will be crucial to navigating this complex market successfully. For more insights, visit The Oregon Group's website at www.theoregongroup.com or follow them on LinkedIn and Twitter. To stay connected with Anthony Milewski, visit www.anthonymilewski.com or follow him on Twitter/X. Follow The Oregon Group on LinkedIn and Twitter. Disclaimer  1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector.  2) The Article was issued on behalf of and sponsored by, The Oregon Group. Market Jar Media Inc. has or expects to receive from The Oregon Group’s Digital Marketing Agency of Record (Native Ads Inc) one thousand five hundred USD for this article.  3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy  4) The Article does not constitute investment advice. All investments carry risk and each reader is encouraged to consult with his or her individual financial professional. Any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.’s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on PressReach.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on PressReach.com  5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article.  6) This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect management’s expectations regarding The Oregon Group.’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to The Oregon Group.’s industry; (b) market opportunity; (c) The Oregon Group’s business plans and strategies; (d) services that The Oregon Group intends to offer; (e) The Oregon Groups milestone projections and targets; (f) The Oregon Group’s expectations regarding receipt of approval for regulatory applications; (g) The Oregon Group’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) The Oregon Group’s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute The Oregon Group’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) The Oregon Group’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) The Oregon Group’s ability to enter into contractual arrangements with additional parties; (e) the accuracy of budgeted costs and expenditures; (f) The Oregon Group’s ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of The Oregon Group to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) The Oregon Group’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact The Oregon Group’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing The Oregon Group’s business operations (e) The Oregon Group may be unable to implement its growth strategy; and (f) increased competition.  Except as required by law, The Oregon Group undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does The Oregon Group nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither The Oregon Group nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document.  7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of The Oregon Group or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of The Oregon Group or such entities and are not necessarily indicative of future performance of The Oregon Group or such entities.  8) Investing is risky. The information provided in this article should not be considered as a substitute for professional financial consultation. Users should be aware that investing in any form carries inherent risks, and as such, there is a possibility of losing some or all of their investment. The value of investments can fluctuate significantly within a short period, and investors must understand that past performance is not indicative of future results. Additionally, users should exercise caution as transactions involving investments may be irreversible, even in cases of fraud or accidental actions. It is crucial to acknowledge that rapidly evolving laws and technical issues can have adverse effects on the usability, transferability, exchangeability, and value of investments. Furthermore, users must be cognizant of potential security risks associated with their investment activities. Individuals are strongly encouraged to conduct thorough research, seek professional advice, and carefully evaluate their risk tolerance before engaging in any investment endeavors. Market Jar Media Inc. is neither an investment adviser nor a broker-dealer. The information presented on the website is provided for informative purposes only and is not to be treated as a recommendation to make any specific investment. No such information on PressReach.com constitutes advice or a recommendation. Contact Details James Young +1 800-340-9767 campaigns@pressreach.com Company Website https://pressreach.com

September 10, 2024 10:00 AM Eastern Daylight Time

Image
Article thumbnail News Release

This Company Is Betting On Innovation To Make A Splash In Multiple Healthcare Markets And It Hit Multiple Milestones This Year

Benzinga

By James Blacker, Benzinga Therma Bright Inc. (OTC: TBRIF), a growing player in the healthcare industry, is making visible strides with its diverse portfolio of innovative medical devices and diagnostic solutions designed to address unmet clinical needs. With its flagship product the Venowave VW5, a product designed to enhance blood circulation, Therma Bright is aiming to capitalize on a deep vein thrombosis (DVT) treatment market expected to grow to $1.62 billion by 2032. Beyond this, the company’s ambitions expand to developing cutting-edge technology to tackle a variety of health challenges, from respiratory disease management to pain relief. Over 2024, Therma Bright secured multiple milestones that indicate the growing attention it is receiving. The Venowave: A Potential Game-Changer in DVT Prevention The Venowave VW5 is an FDA-approved circulation booster designed to improve circulation in the lower extremities. Worn on the calf, the lightweight device stimulates blood flow with wave-like motions that massage the leg, forcing blood from the feet and legs back to the heart and preventing the formation of blood clots. This is particularly effective in cases of DVT, a condition that affects up to 900,000 people in the U.S. and that, if left untreated, can lead to serious complications such as a pulmonary embolism. Beyond just DVT, the Venowave has a range of other healthcare applications, such as managing symptoms of post-thrombotic syndrome, preventing primary thrombosis and treating lymphedema. In an encouraging sign for the product, Therma Bright announced on 27 August that it has secured a nationwide U.S. distribution partner for Venowave. Subject to the success of an initial sales program, this unnamed partner has committed to acquiring inventory worth $2.38 million. Also in August, Therma Bright received the permanent Healthcare Common Procedure Coding System (HCPCS) code from the U.S. Department of Health & Human Services' Centers for Medicare and Medicaid Services (CMS). This crucial designation increases the product’s credibility and could be a key catalyst to help propel Therma Bright to a leadership position in the DVT treatment market. Preva®: Clot Retrieval For Stroke Treatment The global coronary stents market was estimated to be $8.82 billion in 2022 and is expected to grow at a compound annual growth rate of 7.82% to reach $16.14 billion by 2030. Positioning itself to take a share of this growing market, Therma Bright has added to its diverse portfolio of late-stage products by investing in Inretio, the developer of the Preva® clot-retrieval device. The company hopes this device will revolutionize ischemic stroke treatment by improving effectiveness and preventing complications during thrombectomy procedures. The technology, which recently completed its third successful human trial, promises to offer a new approach to clot retrieving that reduces the need for repeated maneuvers and minimizes the risk of embolization. With more than 690,000 ischemic stroke patients in the U.S. each year, this potentially game-changing device could be the breakthrough in clot retrieval needed to significantly improve their lives. Another Growth Opportunity In The COPD Market Another of Therma Bright’s ventures that may hold promise is its stake in InStatin, a company developing inhaled statin therapies for conditions such as asthma and chronic obstructive pulmonary disease (COPD). Unlike traditional oral therapies, InStatin targets the lungs directly, and the company hopes to provide a more effective treatment option for a range of respiratory conditions that affect millions of people worldwide. With the COPD market alone estimated to be worth over $16 billion annually, Therma Bright could stand to benefit from InStatin’s growth trajectory as its therapies advance through pre-clinical trials. Therma Bright previously owned a 17% stake in InStatin, but this percentage is set to increase as the company recently announced that it has expanded its investment. More In The Pipeline Therma Bright’s innovation pipeline doesn’t stop there. Other products in development include a Digital Cough Test app developed in partnership with AI4LYF. The app uses AI to monitor respiratory diseases based on the sound of a person’s cough. The cough data is reviewed by a doctor via an AI dashboard who can use the information to then treat the patient. Other products in Therma Bright’s portfolio include the Benepod™ Hot & Cold Contrast Therapy Device for Pain Relief, the AcuVid™ COVID-19 Rapid Antigen Test Solution, InterceptCS™ for at-home cold sore prevention and the TherOZap™ thermal therapy for insect bite relief. Why You May Want To Keep An Eye On Therma Bright With the global DVT market expected to reach $1.5 billion by 2032 and other innovations like the Preva® device and inhaled statins addressing multi-billion-dollar markets, Therma Bright could be well-positioned to capture a significant market share in multiple growing markets. Investors may want to keep an eye on this small company with a current market cap of about $20 million whose stock has rallied over 350% this year (as of Sep. 5) as it expands its presence in industries worth billions of dollars. Featured photo by Narupon Promvichai from Pixabay. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 10, 2024 08:58 AM Eastern Daylight Time

Image
Article thumbnail News Release

Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF): Major Approvals Make TBRIF A Stock To Watch

TBRIF

The medical device sector is experiencing rapid growth, driven by technological advancements and rising global healthcare needs. According to Statista, the global market is set to expand at an annual rate of 5.71%, reaching $673.10 billion by 2029. In 2024 alone, the United States is expected to generate $179.80 billion in medical device revenues, underscoring the sector’s substantial potential. In this burgeoning market, Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) stands out as an emerging leader. The company has made notable progress in diagnostics and health-tech solutions, with recent milestones such as the approval of reimbursement for its Venowave VW5 device. These developments highlight Therma Bright’s strong growth potential and its ability to open new revenue streams in the healthcare and medical technology sectors. Reimbursement Approval: A Game-Changer for Revenue On August 19, 2024, Therma Bright announced a landmark achievement with the U.S. Centers for Medicare and Medicaid Services (CMS) granting permanent Healthcare Common Procedure Coding System (HCPCS) code E0683 to its Venowave VW5 device. This approval signifies a major breakthrough, as it not only provides a specific reimbursement code but also sets a precedent for the device's integration into the U.S. healthcare system. Rob Fia, CEO of Therma Bright, expressed his enthusiasm about the development: "We're pleased that the Centers for Medicare and Medicaid have approved our permanent code request, as well as the reimbursement pricing and the new HCPCS Level II designation for our Venowave VW5 device." This approval ensures that Venowave VW5 will be reimbursed for up to $1,199 per device or $78.05 per month for rental, totaling up to $819.55 over 13 months. The device addresses critical circulatory issues, including deep vein thrombosis (DVT), a condition affecting over 900,000 U.S. citizens annually. The reimbursement approval opens a major revenue channel for Therma Bright. Market research projects that the global market for DVT-related treatments will reach $1.5 billion by 2032. With the Venowave VW5 device being the first of its kind to receive a permanent HCPCS code, Therma Bright is poised to capture a significant share of this expanding market. Strategic Investments and Expanding Market Reach In addition to the reimbursement milestone, Therma Bright has been actively expanding its footprint through strategic investments and partnerships. On August 22, 2024, the company announced the securing of a nationwide U.S. distribution partner for the Venowave VW5. This partner will launch an initial sales program to assess Medicare/Medicaid reimbursement timelines and billing procedures, with a commitment to acquire inventory valued at up to $2.38 million post-program success. The partnership is a testament to the confidence in Venowave’s market readiness and the anticipated success of the reimbursement process. Rob Fia highlighted the significance of this deal: "We are thrilled to welcome our nationwide distribution partner to our team... We expect the program to be successful, leading to a significant increase in Venowave orders on a monthly basis and accelerating our revenue growth." Innovative Technological Advancements Therma Bright’s innovative approach extends beyond Venowave. On August 16, 2024, the company revealed that its AI-powered Digital Cough Technology (DCT) is under consideration for a clinical trial involving a new chronic cough drug. This AI-driven platform aims to enhance data collection and clinical decision-making, showcasing Therma Bright’s commitment to advancing healthcare technology. Additionally, Therma Bright continues to make strategic investments in cutting-edge solutions. On August 6, 2024, the company increased its investment in InStatin, a firm developing an inhaled statin for chronic lung conditions. This move not only boosts Therma Bright’s stake but also positions the company to benefit from potential breakthroughs in asthma and COPD treatments. Leadership and Future Prospects The company’s progress is further supported by recent additions to its advisory board. On August 13, 2024, Therma Bright welcomed Michael Raimondo, a seasoned expert in medical sales and operations, to its advisory board. Raimondo’s extensive experience is expected to drive sales growth and navigate the complexities of U.S. healthcare reimbursement processes. Rob Fia commented on Raimondo’s appointment: "We are pleased that Michael has agreed to join Therma Bright's Advisory Board, where his skills and experience in sales and operations will aid in the company’s sales efforts of its health-tech and med-tech devices." Conclusion Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) is poised for significant growth following the approval of the HCPCS code for its Venowave VW5 device. This milestone opens up opportunities in the large DVT treatment market. With strategic investments, new partnerships, and technological advancements, TBRIF is well-positioned for future success, potentially making it a compelling stock for investors Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and has been compensated by Therma Brite to assist in the production and distribution of content related to TBRIF. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 mark@razorpitch.com Company Website https://razorpitch.com/

September 09, 2024 06:00 AM Eastern Daylight Time

Article thumbnail News Release

Prescribing The Future: How MangoRx Is Shaking Up Telemedicine With A Fresh Platform

Benzinga

By Anthony Termini, Benzinga Since Covid-19, telemedicine has been expanding significantly, with 44% of physicians using it at least weekly and 40% daily in the U.S. in 2023. The industry is seen by some as a new frontier for patient education and access to medicine and care. The DEA Opens The Digital Door To The Telemedicine Industry Before the pandemic, the primary way a patient would get a drug prescription was through an in-person visit with a doctor. The Drug Enforcement Agency (DEA) loosened those restrictions, allowing physicians to prescribe “controlled medications” over the phone and via video conference. That’s been good for companies in the direct-to-consumer telehealth industry. One of the players in this business is MangoRx or Mangoceuticals, Inc. (NASDAQ: MGRX), which develops a variety of men's health and wellness products and services. Working with Surescripts, which helps coordinate all the parties in the prescription process, MangoRx recently transitioned its telemedicine platform to a newly developed DEA-approved telemedicine operating system. The new system allows MangoRx’s third-party doctor network to prescribe and offer controlled substances. These include Prime Protocol by MangoRx, powered by Kyzatrex, an Oral Testosterone Replacement Therapy and other hormone replacement treatments. According to Jacob Cohen, CEO and co-founder of MangoRx, the company is dedicated to “revolutionizing patient care,” and the new system enhances patient management by “offering seamless doctor visits, prescription auto-refills, and overall health management.” MangoRx is joined in the telehealth space by companies like Hims & Hers Health (NYSE: HIMS), a San Francisco-based telehealth company; Maximus Tribe, a compound pharmaceuticals company that also offers coaching and is based in Santa Monica, California; and Nu Image Medical, a Tampa, Florida-based company that sells weight loss, hormone replacement, sexual health, and general wellness products. Cohen argues, however, that MangoRx is setting a new benchmark for excellence in telemedicine. The company believes that the steps it is taking create meaningful competitive advantages over other companies in the space. MangoRx’s Digital Leap Shortens Time To Market MangoRx, which currently offers therapy options for erectile dysfunction, hair growth and hormone replacement, intends to use the new operating system to roll out new weight loss treatment options. These include an oral dissolvable GLP-1 tablet that includes Semaglutide and Tirzepatide, the ingredients in some of the most popular prescription weight loss medicines. The company’s new operating system helps it accelerate the ability to introduce other new product lines, the first of which is the dissolvable tablet they have branded as Slim and Trim. This brand will help MangoRx capitalize on the significant demand for GLP-1 weight loss treatments for both men and women. MangoRx expects these products will be available to patients before the end of the third quarter and that this new addition will help it to substantially grow revenue moving forward. The company says its new operating system will enable it to respond quickly to market needs and marks an important milestone for MangoRx, representing a significant advancement in its capabilities. Amanda Hammer, COO of MangoRx, says that the company has a “commitment to regulatory compliance and innovation” and that the new operating system’s cutting-edge technology puts it in a position to continue “revolutionizing patient care in the telemedicine industry.” MangoRx notes that the system is fully HIPAA-compliant to ensure that all operations adhere to stringent regulatory standards. The new system includes robust security measures to protect patient data and maintain the highest levels of confidentiality. The system upgrade accompanies a redesigned website with an improved user interface to optimize the customer experience and enhance workflows. The combination creates real-time data tracking and seamless integration that enhance operational efficiency and improve patient engagement. Featured photo by LinkedIn Sales Solutions on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 05, 2024 08:50 AM Eastern Daylight Time

Image
1 ... 910111213 ... 513